Company news
Sutro Biopharma, Inc. (NASDAQ:STRO) news
Sutro Biopharma, Inc. news releases on 6ix. Latest, Jun 3, 2023: Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab…
Press releases — page 2
Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1
June 2, 2023
Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
May 14, 2023
Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer
April 26, 2023
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
March 29, 2023
Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer
February 27, 2023
Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
January 8, 2023
Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022
December 9, 2022
Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones
November 7, 2022
Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
November 2, 2022
Sutro Biopharma Announces Departure of Chief Medical Officer
October 23, 2022
Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones
August 7, 2022
Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck
July 25, 2022
Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs
July 11, 2022
Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones
May 8, 2022
Sutro Biopharma Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022
April 7, 2022
Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones
February 27, 2022
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
January 4, 2022
Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China
December 26, 2021
Sutro Biopharma Announces Appointment of Heidi Hunter to Board of Directors
November 16, 2021
Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones
November 9, 2021
Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China
October 11, 2021
Sutro Biopharma Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck
September 29, 2021
Sutro Biopharma Announces Expansion of Leadership Team
September 15, 2021
Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer
August 17, 2021
Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones
August 8, 2021
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
August 8, 2021
Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany
May 31, 2021
Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021
May 18, 2021
Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones
May 6, 2021
Sutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific Officer
April 19, 2021
Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck
April 14, 2021
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
March 21, 2021
Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones
March 17, 2021
Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer
January 20, 2021
Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares
December 10, 2020
Sutro Biopharma Announces Pricing of $126.0 Million Public Offering
December 7, 2020
Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock
December 6, 2020
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
December 2, 2020
Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors
November 30, 2020
Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
November 23, 2020
Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
November 17, 2020
Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments
November 4, 2020
Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global Meeting
September 1, 2020
Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
August 24, 2020
Sutro Biopharma Announces Two Executive Promotions to Vice President of Quality and Vice President of Manufacturing
August 10, 2020
Sutro Biopharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights and Developments
August 5, 2020
Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller
May 20, 2020
Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
May 13, 2020
Sutro Biopharma Announces Proposed Public Offering
May 10, 2020
Sutro Biopharma Announces Pricing of $85.3 Million Public Offering
May 10, 2020